HEARTSCIENCES INC
HSCSNASDAQTrading Snapshot
- Day Range
- $3.22 – $3.42
- 52-Week Range
- $1.63 – $5.25
- Volume (shares)
- 25,569
- Avg Volume (shares)
- —
- Shares Outstanding
- 5.0M
- Next Earnings
- 2026-12-21
Fundamentals Snapshot
- Annual Revenue
- $4,319
- Last Q Revenue
- $2,100
- P/E Ratio
- —
- P/S Ratio
- 3606.0x
- EPS (TTM)
- $-3.21
- Dividend Yield
- —
- Dilution (1yr)
- +186.2%
HEARTSCIENCES INC
HSCS
StockOtter · stockotter.spaceAbout HEARTSCIENCES INC
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
Here is how HeartSciences Inc. (HSCS) and ImmunityBio (IBRX) have performed compared to their sector so far this year.
HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining
Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transaction HeartSciences Board of Directors unanimously recommends shareholders vote FOR the transaction-re
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (
Fortitude Appoints Kimberly Pittman as Chief Legal Officer
FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. (“Fortitude” or the “Company”), a vertically-integrated digital asset mining platform anchored in Zcash, today announced the appointment of Kimberly Pittma
HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
HeartSciences Inc. (HSCS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.58 per share a year ago.